Literature DB >> 8894584

Antibacterial activity of trovafloxacin against gram-positive blood culture isolates from nosocomial infections.

S M Qadri1, Y Ueno.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8894584     DOI： 10.1007/bf01691163

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  6 in total

1.  Coagulase-negative staphylococcal bacteremia. Mortality and hospital stay.

Authors:  M A Martin; M A Pfaller; R P Wenzel
Journal:  Ann Intern Med       Date:  1989-01-01       Impact factor: 25.391

2.  Hospital-acquired candidemia. The attributable mortality and excess length of stay.

Authors:  S B Wey; M Mori; M A Pfaller; R F Woolson; R P Wenzel
Journal:  Arch Intern Med       Date:  1988-12

3.  In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.

Authors:  G M Eliopoulos; K Klimm; C T Eliopoulos; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

4.  In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.

Authors:  T D Gootz; K E Brighty; M R Anderson; B J Schmieder; S L Haskell; J A Sutcliffe; M J Castaldi; P R McGuirk
Journal:  Diagn Microbiol Infect Dis       Date:  1994-08       Impact factor: 2.803

Review 5.  The evolution of fluorinated quinolones: pharmacology, microbiological activity, clinical uses, and toxicities.

Authors:  C Siporin
Journal:  Annu Rev Microbiol       Date:  1989       Impact factor: 15.500

6.  Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System.

Authors:  S N Banerjee; T G Emori; D H Culver; R P Gaynes; W R Jarvis; T Horan; J R Edwards; J Tolson; T Henderson; W J Martone
Journal:  Am J Med       Date:  1991-09-16       Impact factor: 4.965
  6 in total
  1 in total

1.  Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.

Authors:  H P Endtz; J W Mouton; J G den Hollander; N van den Braak; H A Verbrugh
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.